Eleven organisations representing patients across the UK and Europe have warned EU negotiators about the risks Brexit poses to European patients.
In partnership with the UK-based Association of Medical Research Charities, IPPOSI and nine other organisations have sent a letter (included below) to Brexit negotiators Michel Barnier and David Davis. The letter outlines four areas of concern to all European patients, irrespective of their country of residence:
- Achieve close cooperation on medicines regulation to ensure safety and early access to innovative new treatments
- Don’t let trade agreements restrict the supply of medicines and medical devices
- Make sure patients across the EU can access Europe-wide clinical trials – this type of multi-nation collaboration is key to research
- Ensure a smooth transition to deliver changes as seamlessly as possible.
The signatories to the letter (listed below) cite the future of European clinical research as being particularly important. For some patients, particularly those with a rare or less common disease, working together across nations is the only way that sufficient expertise and patient numbers can be brought together to progress research. It’s vital that patients across the EU can continue to take part in pioneering clinical trials.
IPPOSI Chief Executive Derick Mitchell said:
“The impact of Brexit on patients both in the UK and across the EU is significant and has not been sufficiently considered in negotiations to date. Any future regulatory alignment between the EU and UK must ensure sufficient and timely supply of medicines and medical devices. It must not exacerbate delays in access to the most innovative treatments for patients. In the interests of patients and public health, patient voices should be heard loud and clear by negotiators on both sides.”
- Nicola Bedlington, Secretary General, European Patients’ Forum
- Nina Renshaw, Secretary General, European Public Health Alliance
- Wendy Yared, Director, Association of European Cancer Leagues
- Susanne Logstrup, Director, European Heart Network
- Derick Mitchell, Chief Executive, Irish Platform for Patient Organisations, Science & Industry
- Aisling Burnand MBE, Chief Executive, Association of Medical Research Charities
- Jeremy Taylor, Chief Executive, National Voices
- Simon Gillespie, Chief Executive, British Heart Foundation
- Sir Harpal Kumar, Chief Executive, Cancer Research UK
- Jayne Spink PhD Chief Executive, Genetic Alliance UK,
- Roisin Foster, Chief Executive, Cancer Focus Northern Ireland